A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when vaccinated 4 weeks before birth
- Antibodies from the mother passed through placenta protect newborns from birth
- Protection achievable with two-week gap before premature birth
- Vaccination during the third trimester still offers meaningful infant protection
Persuasive evidence from current research
The performance of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation carried out throughout England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that half-year window, providing comprehensive and reliable information of the vaccine’s practical effectiveness. The study’s findings have been supported by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and prospective parents with confidence in the vaccine’s established performance across diverse populations and circumstances.
The results present a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the great majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s essential role in reducing the risk of serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology measured real-world outcomes rather than experimental conditions, providing tangible evidence of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its threats
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it dangerously difficult for infected babies to feed and breathe properly. Parents commonly see their babies visibly struggling, their chests heaving as they try to pull enough air into their damaged lungs. Whilst the majority of babies improve through palliative treatment, a limited though important group succumb from respiratory syncytial virus complications each year, making vaccination as prevention a vital health service objective for safeguarding the youngest and most vulnerable individuals in the population.
- RSV causes inflammation in lungs, resulting in serious respiratory problems in infants
- Approximately half of newborns catch the virus during their first few months alive
- Symptoms span from mild colds to life-threatening chest infections needing hospital treatment
- Over 20,000 UK infants require serious hospital care for RSV annually
- A small number of infants succumb to RSV complications each year in the UK
Take-up rates and professional guidance
Since the RSV vaccine programme launched in 2024, health officials have emphasised the value of pregnant women receiving their jab at the best time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for ensuring newborns receive the maximum immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies passed to their babies through the placenta.
The guidance from public health bodies remains clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional variations in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and availability of the jab. These geographical variations reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the national data shows consistently strong protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to engage with expectant mothers
- Inconsistencies across regions in immunisation take-up in different parts of England demand focused enhancement
- Community health services modifying schemes to align with specific population needs
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness delivers real advantages for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the introduction of this protective measure, the 80% decrease in admissions means thousands of infants protected against critical disease. Parents no more face the troubling prospect of watching their newborns struggle for breath or difficulty feeding, symptoms that characterise critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal lung health, giving expectant mothers a active means to shield their youngest infants during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s advocacy for the jab underscores the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to women in pregnancy during their late pregnancy, converting what was once an inevitable seasonal threat into a controllable health concern.